Gemifloxacin Mesylate is an antibiotic belonging to the fluoroquinolone class, specifically designed to treat a variety of
bacterial infections. Marketed under trade names such as Factive, it targets bacterial pathogens by disrupting their DNA replication process. Developed and researched by pharmaceutical companies including
LG Life Sciences and
Oscient Pharmaceuticals, Gemifloxacin Mesylate has gained approval in various regions for its efficacy against
respiratory tract infections. These include
acute bacterial exacerbation of chronic bronchitis (ABECB) and
community-acquired pneumonia (CAP). Its development has been backed by extensive clinical trials, and it is approved for use in adults to combat
infections caused by susceptible strains of designated microorganisms.
Gemifloxacin Mesylate works by inhibiting bacterial DNA gyrase and
topoisomerase IV, two critical enzymes involved in bacterial DNA replication, transcription, repair, and recombination. By blocking these enzymes, Gemifloxacin causes breaks in bacterial DNA, preventing the bacteria from multiplying and ultimately leading to their death. This dual mechanism of action makes it highly effective against a broad spectrum of Gram-positive and Gram-negative bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, which are common culprits in respiratory infections. Its unique mechanism also helps in reducing the likelihood of developing antibiotic resistance, a significant concern in contemporary medical practice.
Gemifloxacin Mesylate is typically administered orally in tablet form, with a recommended dosage of 320 mg once daily. The duration of treatment usually varies depending on the type and severity of the infection but generally ranges from five to seven days. It is crucial to follow the prescribed dosage and complete the entire course of treatment even if symptoms improve before the medication is finished. This helps ensure the infection is fully eradicated and reduces the risk of developing resistant bacterial strains. The drug is rapidly absorbed, with peak plasma concentrations occurring approximately one to two hours after ingestion. Food does not significantly affect the absorption of Gemifloxacin, so it can be taken with or without meals. However, it is advisable to take it at the same time each day to maintain consistent therapeutic levels in the bloodstream.
Like all medications, Gemifloxacin Mesylate can cause side effects, although not everyone experiences them. Common side effects include
diarrhea,
nausea,
headache,
dizziness, and
rash. These are usually mild and transient but should be reported to a healthcare provider if they persist or worsen. More serious side effects, although rare, can include
tendonitis and
tendon rupture, particularly in older adults or those taking corticosteroids. Gemifloxacin has also been associated with QT interval prolongation, which can lead to
serious heart rhythm disturbances. Therefore, it is contraindicated in patients with a history of
QT prolongation or those taking medications known to prolong the QT interval. Other contraindications include known hypersensitivity to Gemifloxacin or other fluoroquinolones. It is also advised to use this medication with caution in patients with a history of
seizures or
central nervous system disorders, as it may exacerbate these conditions.
Several drugs can interact with Gemifloxacin Mesylate, potentially altering its effectiveness or increasing the risk of side effects. Antacids containing magnesium or aluminum, as well as supplements containing iron or zinc, can interfere with the absorption of Gemifloxacin, reducing its efficacy. Therefore, it is recommended to take Gemifloxacin at least two hours before or three hours after taking these products. Nonsteroidal anti-inflammatory drugs (NSAIDs) like
ibuprofen and
naproxen can increase the risk of central nervous system stimulation and seizures when taken with Gemifloxacin. Additionally, drugs that prolong the QT interval, such as certain antiarrhythmics, antidepressants, and antipsychotics, should be used with caution when taking Gemifloxacin due to the increased risk of serious heart rhythm disturbances. It is always important to inform healthcare providers of all medications and supplements being taken to avoid potential drug interactions.
How to obtain the latest development progress of all drugs?
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!


